海普瑞:与永太药业签订分销协议 获加巴喷丁胶囊美国商业化许可

南方财经网
02 Jan

  南方财经1月2日电,海普瑞公告,公司于2024年12月31日与永太药业签订分销协议,永太药业授予海普瑞在美国全境商业化加巴喷丁胶囊(Gabapentin)的许可。海普瑞将向永太药业以约定价格购买该标的药品,并负责标的药品在美国市场的商业化工作。加巴喷丁是一种常用的抗癫痫药物,被广泛用于治疗神经痛和其他疼痛性疾病。本次合作是海普瑞坚持国际化经营及助力中国药企药品出海欧美市场战略的体现与探索。公司将负责标的药品在合作区域内商业化并承担相关费用,商业化推广能否取得预期效益存在不确定性。

(文章来源:南方财经网)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10